Principal Investigators

    Prof. dr. S.E.J.A. de Rooij

    Institution

    Academisch Medisch Centrum

    Contact information of lead PI

    Country

    Netherlands

    Title of project or programme

    Hospital At Home care program for patients with dementia and an acute medical crisis

    Source of funding information

    ZonMw

    Total sum awarded (Euro)

    € 400,000

    Start date of award

    01/12/2014

    Total duration of award in years

    3.0

    The project/programme is most relevant to:

    Alzheimer's disease & other dementias

    Keywords

    Research Abstract

    OBJECTIVE: The H@H trial investigates the balance of costs and clinical effects in terms of complications and mortality between H@H care
    and conventional hospital care
    HYPOTHESIS
    H@H care reduces costs, complications and mortality in dementia patients admitted to the ED for hospitalization with selected
    acute medical illnesses who require acute hospital-level care.
    STUDY DESIGN
    Multicentre randomized controlled, parallel-group superiority trial.
    STUDY POPULATION: In total 266 patients aged 65 years or above, known with a diagnosed dementia syndrome.
    INTERVENTION: H@H vs conventional hospital care.
    OUTCOME MEASURES: Primary endpoint: composite endpoint of severe complications (readmission to hospital) and mortality within 6 months after randomisation.
    Secondary endpoints: costs, budget impact, functional status and functional decline, quality of life in terms of quality-adjusted life years (QALYs), incidence of all individual components of the primary endpoint, admission to nursing home, length of hospital stay after readmission, new onset intensive care admission, length of intensive care stay, any complications [falls, new infections], number of endoscopic, radiological and operative (re-) interventions.

    COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS
    Cost-effectiveness and cost-utility analyses from a societal perspective with the costs per patient with poor outcome (severe complications and/or death) and costs per QALY as primary outcome measures respectively. Budget impact analyses from governmental, insurer, and provider perspectives.

    Lay Summary

    Further information available at:

Types: Investments > €500k
Member States: Netherlands
Diseases: Alzheimer's disease & other dementias
Years: 2016
Database Categories: N/A
Database Tags: N/A

Export as PDF